聚乙二醇化干扰素α-2a与拉米夫定治疗e抗原阴性慢性乙型肝炎的药物经济学评价

Economic evaluation of peginterferon Alfa-2a and lamivudine in the treatment of HBeAg-negative chronic hepatitis B

目的评估聚乙二醇化干扰素α-2a与拉米夫定治疗e抗原阴性慢性乙型肝炎的成本效果。方法收集相关文献资料,并经Delphi法专家咨询,运用Markov模型对聚乙二醇化干扰素α-2a与拉米夫定治疗慢性乙型肝炎进行经济学评价。结果与使用拉米夫定1年相比,聚乙二醇化干扰素α-2a治疗e抗原阴性慢性乙型肝炎患者1年,人均延长寿命0.93年,每延长1年寿命所需增加的医疗费用为16675元。结论与拉米夫定相比,使用聚乙二醇化干扰素α-2a1年治疗e抗原阴性慢性乙型肝炎具有较好的成本效果。

Objective To assess the long-term cost-effectiveness of pegintefferon Alfa-2a and lamivudine in the treatment of HBeAg-negative chronic hepatitis B. Methods A Markov model was employed to conduct the economic evaluation based on the data retrieved from literatures and verified through Delphi method. Results Compared with one-year lamivudine treatment, one-year peginterferen Alfa-2a treatment can prolong 0.93 year for every HBeAg-negative CHB patient and the incremental medical cost was 16,675 RMB per life-year saved. Concluslon Pegintefferon Alfa-2a is more cost effective than lamivudine in the treatment of HBeAg- negative chronic hepatitis B.